Belimumab: a guide to its use in systemic lupus erythematosus.

Article Details

Citation
Copy to clipboard

Scott LJ, Burness CB, McCormack PL

Belimumab: a guide to its use in systemic lupus erythematosus.

BioDrugs. 2012 Jun 1;26(3):195-9. doi: 10.2165/11209060-000000000-00000.

PubMed ID
22428610 [ View in PubMed
]
Abstract

Belimumab (Benlysta(R)), a fully human recombinant IgG1lambda monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.

DrugBank Data that Cites this Article

Drugs